U.S. Markets open in 44 mins

Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 211% In The Last Three Years

Simply Wall St

The most you can lose on any stock (assuming you don’t use leverage) is 100% of your money. But in contrast you can make much more than 100% if the company does well. For instance the Global Blood Therapeutics, Inc. (NASDAQ:GBT) share price is 211% higher than it was three years ago. That sort of return is as solid as granite. Also pleasing for shareholders was the 17% gain in the last three months. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report.

Check out our latest analysis for Global Blood Therapeutics

Global Blood Therapeutics didn’t have any revenue in the last year, so it’s fair to say it doesn’t yet have a proven product (or at least not one people are paying for). As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. For example, they may be hoping that Global Blood Therapeutics comes up with a great new treatment, before it runs out of money.

We think companies that have neither significant revenues nor profits are pretty high risk. The is usually a significant chance that they will need more money for business development, putting them at the mercy of capital markets. So the share price itself impacts the value of the shares (as it determines the cost of capital). While some such companies go on to make revenue, profits, and generate value, others get hyped up by hopeful naifs before eventually going bankrupt. Some Global Blood Therapeutics investors have already had a taste of the sweet taste stocks like this can leave in the mouth, as they gain popularity and attract speculative capital

Global Blood Therapeutics has plenty of cash in the bank, with net cash sitting at US$433m, when it last reported (December 2018). That allows management to focus on growing the business, and not worry too much about raising capital. And given that the share price has shot up 46% per year, over 3 years, its fair to say investors are liking management’s vision for the future. The image belows shows how Global Blood Therapeutics’s balance sheet has changed over time; if you want to see the precise values, simply click on the image.

NasdaqGS:GBT Historical Debt, March 8th 2019

It can be extremely risky to invest in a company that doesn’t even have revenue. There’s no way to know its value easily. Given that situation, many of the best investors like to check if insiders have been buying shares. It’s usually a positive if they have, as it may indicate they see value in the stock. You can click here to see if there are insiders buying.

A Different Perspective

Over the last year, Global Blood Therapeutics shareholders took a loss of 13%. In contrast the market gained about 0.9%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Fortunately the longer term story is brighter, with total returns averaging about 46% per year over three years. Sometimes when a good quality long term winner has a weak period, it’s turns out to be an opportunity, but you really need to be sure that the quality is there. Before spending more time on Global Blood Therapeutics it might be wise to click here to see if insiders have been buying or selling shares.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.